Array BioPharma Stock – Fundamental Analysis
Not enough price data available yet.
Fundamental Data & Ratios (Balance sheet update: 9/29/2018)
| Balance Sheet | Total Assets | 923,581,000.00 | ROE | – |
| Balance Sheet | Total Equity | 305,151,000.00 | ROA | – |
| Cashflow | Capital Expenditures | 0.00 | P/FCF | – |
| Cashflow | Free Cash Flow | 386,073,000.00 | – | – |
| Cashflow | Operating Cash Flow | 386,073,000.00 | P/CF | – |
| Income | Earnings per Share (diluted) | -0.74 | Div. Yield | – |
| Income | Net Income | 39,745,000.00 | P/E | – |
| Income | Shares Outstanding | 198,490,000.00 | P/B | – |
| Income | Total Revenue | 647,899,000.00 | P/S | – |
Ratios calculated on: –
Company Description
Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule drugs to treat patients afflicted with cancer and inflammatory diseases. The drug development pipeline includes clinical candidates that are designed to regulate therapeutically important target pathways. The Company´s drug candidates include AMG 151, MEK162, ARRY-380, ARRY-520, ARRY-543 and ARRY-614.
Additional comparison and history views are available after login.
Finanzoo GmbH assumes no liability for the accuracy of the information provided! All information is provided without guarantee. Sources: www.bundesanzeiger.de, www.sec.gov, www.arraybiopharma.com
All metrics and scores are an automated evaluation and not investment advice or a recommendation to buy or sell. Finanzoo GmbH or its shareholders may themselves hold positions in the securities shown.
Learn more